- Home
- SUIG vs EDIT Comparison
SUIG vs EDIT Comparison
Compare SUIG & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUIG
- EDIT
- Stock Information
- Founded
- SUIG 2006
- EDIT 2013
- Country
- SUIG United States
- EDIT United States
- Employees
- SUIG N/A
- EDIT N/A
- Industry
- SUIG Finance Companies
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SUIG Finance
- EDIT Health Care
- Exchange
- SUIG Nasdaq
- EDIT Nasdaq
- Market Cap
- SUIG 321.6M
- EDIT 269.8M
- IPO Year
- SUIG N/A
- EDIT 2016
- Fundamental
- Price
- SUIG $4.27
- EDIT $3.95
- Analyst Decision
- SUIG
- EDIT Buy
- Analyst Count
- SUIG 0
- EDIT 11
- Target Price
- SUIG N/A
- EDIT $4.56
- AVG Volume (30 Days)
- SUIG 2.3M
- EDIT 2.8M
- Earning Date
- SUIG 11-11-2025
- EDIT 11-03-2025
- Dividend Yield
- SUIG N/A
- EDIT N/A
- EPS Growth
- SUIG 619.34
- EDIT N/A
- EPS
- SUIG 0.24
- EDIT N/A
- Revenue
- SUIG $3,305,884.00
- EDIT $38,901,000.00
- Revenue This Year
- SUIG N/A
- EDIT N/A
- Revenue Next Year
- SUIG N/A
- EDIT N/A
- P/E Ratio
- SUIG $18.93
- EDIT N/A
- Revenue Growth
- SUIG 1.77
- EDIT N/A
- 52 Week Low
- SUIG $1.13
- EDIT $0.91
- 52 Week High
- SUIG $8.66
- EDIT $4.07
- Technical
- Relative Strength Index (RSI)
- SUIG N/A
- EDIT 71.08
- Support Level
- SUIG N/A
- EDIT $3.01
- Resistance Level
- SUIG N/A
- EDIT $4.06
- Average True Range (ATR)
- SUIG 0.00
- EDIT 0.30
- MACD
- SUIG 0.00
- EDIT 0.08
- Stochastic Oscillator
- SUIG 0.00
- EDIT 89.89
About SUIG Sui Group Holdings Limited Common Stock
Sui Group Holdings Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that the group provides are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.